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Abstract
Background: It is unknown if changes in the gene expression of the desaturase and elongase enzymes are
associated with abnormal n-6 long chain polyunsaturated fatty acid (LC-PUFA) levels in children with atopic eczema
(AE). We analyzed whether mRNA-expression of genes encoding key enzymes of LC-PUFA synthesis (FADS1,
FADS2 and ELOVL5) is associated with circulating LC-PUFA levels and risk of AE in 4-year-old children.
Methods: AE (n=20) and non-AE (n=104) children participating in the Sabadell cohort within the INfancia y Medio
Ambiente (INMA) Project were included in the present study. RT-PCR with TaqMan Low-Density Array cards was
used to measure the mRNA-expression of FADS1, FADS2 and ELOVL5. LC-PUFA levels were measured by fast gas
chromatography in plasma phospholipids. The relationship of gene expression with LC-PUFA levels and enzyme
activities was evaluated by Pearson’s rank correlation coefficient, and logistic regression models were used to study
its association with risk of developing AE.
Results: Children with AE had lower levels of several n-6 PUFA members, dihomo-γ-linolenic (DGLA) and
arachidonic (AA) acids. mRNA-expression levels of FADS1 and 2 strongly correlated with DGLA levels and with D6D
activity. FADS2 and ELOVL5 mRNA-expression levels were significantly lower in AE than in non-AE children
(-40.30% and -20.36%; respectively), but no differences were found for FADS1.
Conclusions and Significance: Changes in the mRNA-expression levels of FADS1 and 2 directly affect blood
DGLA levels and D6D activity. This study suggests that lower mRNA-expressions of FADS2 and ELOVL5 are
associated with higher risk of atopic eczema in young children.
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Introduction
Atopic eczema (AE) is a multifactorial skin disease occurring
most frequently in early childhood. It is caused by a complex
interplay between immunological, genetics, biochemical,
psychological and environmental factors. AE currently affects
15 to 30% of children and 1 to 3% of adults in industrialized
countries, with 85% of cases beginning before the age of five
[1,2].
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Many studies suggest that AE is associated with impairment
in the metabolism of n-6 essential fatty acids (EFAs) and long
chain polyunsaturated fatty acids (LC-PUFAs). Deficits in n-6
EFAs are related to the severity of AE through changes in skin
barrier function and cutaneous inflammation [3-6]. Higher levels
of linoleic acid (LA, C18:2 n-6) and significantly lower levels of
γ- linolenic (GLA, C18:3 n-6), dihomo-γ-linolenic (DGLA, C20:3
n-6) and arachidonic (AA, C20:4 n-6) acids have been noted in
the plasma or serum of AE children compared to healthy
control [3,4,7,8]. The synthesis of LC-PUFAs from LA involves
enzyme-mediated desaturation and elongation steps. Δ6-
desaturase (D6D, encoded by the FADS2 gene) catalyzes the
conversion of LA into GLA, which is then elongated into DGLA
by elongase-5 (encoded by the ELOVL5 gene). Moreover,
DGLA can be converted into AA by Δ5-desaturase (D5D,
encoded by the FADS1 gene) (summarized in Figure 1) [9-13].
According to findings of different studies, defects in the
activity of enzymes involved in LC-PUFAs biosynthesis could
be related to lower concentrations of LA metabolites [7,14].
Recent studies report an association between genetic variants
(Single Nucleotide Polymorphism, SNP) of the FADS1 and
FADS2 gene cluster and LC-PUFA levels in serum, plasma
phospholipids and erythrocyte membranes. Subjects carrying
the minor alleles have higher LA and DGLA levels, and lower
AA concentrations [10,15-17]. Furthermore, a link between
FADS SNPs and atopic outcomes in children, such as AE and
asthma, has been investigated with controversial results.
Rzehak et al.[14], using two population-based birth cohorts,
found that PUFA composition in young children’s blood was
strongly controlled by the FADS gene cluster. These authors
reported that SNPs were significantly associated with eczema
in the LISA, but not the KOALA cohort. On the other hand,
Standl et al. [11] and Sigman et al. [18] concluded that there
was no association between FADS polymorphisms and atopic
diseases in children.
To date, it is unclear whether changes in the expression of
FADS1 and FADS2, and consequently, LC-PUFA levels in
children and adults determine risk of atopic diseases in
humans. To our knowledge, only one study developed by Saaf
et al. [19] reports a reduced gene expression of FADS1 (D5D)
and FADS2 (D6D) in the AE skin of adults. Their results
support the hypothesis that low LC-PUFA levels are due to
impaired desaturase activity and thus, impaired synthesis of
these fatty acids [7]. As far as we know, there are no scientific
Figure 1.  n-6 and n-3 pathways of long chain polyunsaturated fatty acid (LC-PUFA) biosynthesis from essential fatty acids
(EFAs).  Modified from [10,14,33]. LA, linoleic acid; GLA, γ- linolenic acid; DGLA, dihomo-γ-linolenic acid; AA, arachidonic acid;
DTA, docosatetraenoic acid ALA, α-Linolenic acid; SA stearidonic acid; ETA eicosatetraenoic acid; EPA, eicosapentaenoic acid;
DPA, docosapentaenoic acid; DHA, docosahexaenoic acid. D5D (Δ5-desaturase), D6D (Δ6-desaturase) and Elongase-5 enzymes
are encoded by FADS1, FADS2 and ELOVL5, respectively.
doi: 10.1371/journal.pone.0078245.g001
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studies focusing on the mRNA-expression of these genes in
children.
Combining measurements of gene expression, enzyme
activity and polyunsaturated fatty acid levels is essential in
explaining the differences in blood lipid levels of children who
develop atopic diseases. Thus, the aim of this study was to
investigate whether mRNA-expression of genes encoding key
enzymes of LC-PUFA synthesis (FADS1, FADS2 and ELOVL5)




Written informed consent was obtained from all participant
parents and the study was approved by the Clinical Research
Ethical Committee of the Municipal Institute of Health Care
(CEIC-IMAS) and the Hospital of Sabadell, Spain.
Study population and design
Data for this report come from a population-based pregnancy
cohort set up in Sabadell, Spain as part of the INMA Project
[Cohort Profile: The INMA--INfancia y Medio Ambiente--
(Environment and Childhood) Project] [20]. A detailed
description of the Sabadell cohort has been provided
elsewhere [21,22]. A total of 657 children were enrolled
between 2004 and 2006. At 4 years of age a subset of 124
children were included in the present study
During pregnancy and the first 4 years postpartum,
information on maternal education, gender, breastfeeding and
atopic outcomes was collected through questionnaires
administered to the mothers at various time points (12 and 32
weeks of gestation, as well as follow-up at 6 and 14 months
and 4 years postpartum).
Definition of eczema
Information about AE was obtained from the parents through
two questionnaires completed when the child was 14 months
[22] and 4 years old. Three questions were addressed to the
parents: at 14 months old, “has your child ever experienced
atopic eczema since birth to 14 months?” and at 4 years, “has
the child ever experienced atopic eczema in the last 12
months?” and “has the child taken any medication for atopic
eczema in the last 12 months?” AE was defined as recurrent
atopic eczema (reported symptoms during the first year of life
and at 4 years old) and having medication for eczema at age 4
(n=20). Non-AE had no personal history of AE (n=104).
RNA isolation and cDNA synthesis
Venous peripheral blood samples obtained from 4-year-old
children were collected in PAXgene (TM) Blood RNA tubes (BD
company, Germany) to ensure RNA preservation and stored at
-20 and then at -80C before RNA extraction. Total RNA was
isolated from whole blood using the PAXgene Blood RNA Kit
following the manufacturer’s protocol (Qiagen, Hilden,
Germany). RNA concentration was determined using a
spectrophotometer (Nanodrop) and quality (percentage of
miRNAs and RIN) was determined by the Bioanalyzer system
(Agilent, USA). 700 ng of total RNA was reverse-transcribed in
the thermal cycler PTC-100 into cDNA using the SuperScript
cDNA Synthesis Kit, according to the manufacturer’s protocol
(Invitrogen, USA). The reaction mixture was incubated at 25°C
for 10 min and then at 42°C for 60 min. Finally, the mixture was
heated at 85°C for 5 min. cDNA samples were stored at -80°C
prior to analysis.
PCR using TaqMan low-density array cards (TLDAs)
To identify altered gene expression in peripheral blood, we
used PCR with TaqMan Low-Density Array (TLDA) microfluidic
cards (Applied Biosystems, USA). Each port was preloaded
with specific user-defined TaqMan primers and probes. This
technology has been shown to be sensitive and reproducible
for assessing gene expression [23,24]. Although the TLDA
cards were predesigned to measure 24 genes, we only used it
for the genes related to the elongation and desaturation of LC-
PUFAs. Thus, each card contained the target genes ELOVL5
[Hs 01094704_m1, inventoried], FADS1 [Hs 00203685_m1,
inventoried] and FADS2 [Hs 00188654_m1, inventoried].
Additionally, each card contained five endogenous control
genes, PPIB [Hs 00168719_m1, inventoried], FPGS [Hs
00191956_m1, inventoried], TRAP1 [Hs00212474_m1,
inventoried], GAPDH [Hs99999905_m1 inventoried] and β2M
[Hs99999907_m1, inventoried]. The full RT-PCR data set is
available at The NCBI Gene Expression Omnibus (GEO)
Database (GEO accession: GSE48310)
A total of 100 μL of reaction mixture, with 16 μL of cDNA
(560 ng), 34 µL of H2O and 50 μL of TaqMan Universal PCR
Master Mix (Applied Biosystems, USA), was added to each
TLDA port after vortexing. The card was centrifuged for 1 min x
2 at 1900 rpm to distribute the samples from the loading port to
each well. The TLDA was sealed with a TaqMan low-density
array sealer (Applied Biosystems, USA) and the PCR
amplification was performed using an ABI Prism 7900HT
sequence detection system (Applied Biosystems, USA). The
thermal cycler conditions were as follows: 2 min at 50°C, then
10 min at 94.5°C, followed by 40 cycles for 30 s at 97°C and 1
min at 59.7°C. Each sample was measured in duplicate in the
same TLDA card. The SDS software (version 2.4) was used to
analyze the expression data.
The amount of target mRNA relative to the endogenous
control expression and relative to values from the reference
group was calculated using the 2−ΔΔCt method, as previously
described [25]. mRNA-expression levels were normalized using
the expression of peptidylpropyl isomerase B (PPIB) as the
endogenous housekeeping gene, since this gene presented
the highest stability in all the samples. Results were expressed
as the mean of the percentage of these values for the
experimental group (AE children) compared to the reference
group (non-AE children), which represented 100% gene
expression.
Plasma phospholipid fatty acid analysis
The fatty acid composition of plasma phospholipids was
determined according to the method described by Chisaguano
et al. [26]. Fatty acid methyl esters (FAMEs) were prepared
FADS and ELOVL Gene Expressions and Atopic Eczema
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with sodium methylate in 0.5M methanol and boron trifluoride
methanol solution (14% v/v). They were then separated and
quantified by fast gas chromatography with flame ionization
detection (FID). FAMEs were identified by comparing the peak
retention times of the FAME samples with those of the
standard FAME mix solutions. Data acquisition and processing
were performed with the Shimadzu-Chemstation software for
GC systems. The relative amount of each fatty acid quantified
was expressed as the percentage of the total amount of fatty
acids (% total fatty acids).
Enzyme activities were calculated using relevant fatty acid
product:precursor ratios, as previously described [16,21,27].
Thus, the ratios C20:4 n-6/C20:3 n-6 (AA:DGLA) for D5D,
C20:3 n-6/C18:2 n-6 (DGLA:LA) for D6D; C20:3 n-6/C18:3 n-6
(DGLA:GLA) and C22:4 n-6/C20:4 n-6 (DTA:AA) for
Elongase-5 were used .
Statistical analysis
Means and standard deviations (SDs) were used to describe
continuous variables. The Kolmogorov-Smirnov test was used
to study the normal distribution of data and non-normally
distributed data were naturally log-transformed. The differences
in gene expression between the groups were evaluated by
unpaired Student t-test. Correlations between fatty acids,
enzyme activities and mRNA-expression levels were
determined by Pearson’s rank correlation coefficient, while
logistic regression was applied to evaluate the association
between mRNA levels and AE. The confounding variables
were selected based on previous literature data and were
gender, maternal education and breastfeeding [14,21]. All
statistical analyses were performed on SPSS 20.0 for Windows
(SPSS Inc. Chicago, IL, USA).
Results
Population characteristics, PUFA levels and enzyme
activity
The basic population characteristics, n-6 and n-3 LC-PUFA
levels of plasma phospholipids, as well as enzyme activities
(determined as fatty acid ratios) are summarized in Table 1. No
statistical differences were found between AE and non-AE
children for sex, predominant breastfeeding and maternal
education (p> 0.05).
AE children tended to have higher LA levels, but this was not
statistically significant (p= 0.282). Moreover, DGLA and AA
levels were significantly lower in AE children than in controls
(p= 0.014 and p= 0.046, respectively) (Table 1). We observed
no significant differences in the levels of n-3 LC-PUFAs (EPA,
DPA and DHA) between the two groups.
There were no significant differences in D5D activity
(AA:DGLA, p= 0.962) between AE children and control.
However, AE children displayed lower D6D activity (DGLA:LA,
p= 0.002) than controls. On the other hand, there were
significant differences in elongase-5 activity (DTA:AA, p=0.049)
between the two groups.
Relationship between gene expression and fatty acid
levels
There was a positive relationship between the mRNA-
expression levels of FADS1 and FADS2 (r=0.527,
p=4.37E-10), suggesting that both genes are coexpressed.
FADS2 and FADS1 expression positively correlated with DGLA
and GLA levels and with the DGLA:LA ratio.
In contrast, no correlation was found between ELOVL5 (gene
not located in the FADS cluster) and FADS1 or FADS2 mRNA-
expressions. In addition, there was no observed correlation
between ELOVL5 gene expression and LC-PUFA levels or
enzyme activities (Table 2).
Association between activity/mRNA-expression of
enzymes and atopic eczema
Reduced mRNA-expression of the ELOVL5 (-20.36%,
p=0.005) and FADS2 (-40.30%, p=0.013) genes was observed
in the peripheral blood of AE children relative to controls.
FADS1 mRNA-expression was detected in AE children, but its
Table 1. Characteristics of the Sabadell cohort subsample




Gender [% male] 49 60 0.369a
Predominant breastfeeding for at
least 2 weeks [%]
77.7 70 0.460a
Maternal educationт [%] 77.7 66.7 0.313a
1 Fatty acids (mean % of total FA) †    
Linoleic (LA, C18:2 n-6) 25.21 ± 2.26 25.84 ± 2.30 0.282b
γ-Linolenic (GLA, C18:3 n-6) 0.09 ± 0.04 0.09 ± 0.06 0.545b
Dihomo-γ-Linolenic (DGLA, C20:3
n-6)
2.72 ± 0.66 2.40 ± 0.42 0.014b
Arachidonic (AA, C20:4 n-6) 9.48 ± 2.45 8.46 ± 1.77 0.046b
Adrenic (DTA, C22:4 n-6) 0.38 ± 0.10 0.38 ± 0.11 0.920 b
α-Linolenic (ALA, C18:3 n-3) ‡ 0.10 ± 0.04 0.11 ± 0.04 0.423b
Eicosapentanoic (EPA, C20:5 n-3) ‡ 0.31 ± 0.16 0.30 ± 0.39 0.723b
Docosapentaenoic n-3 (DPA, C22:5
n-3)
0.48 ± 0.13 0.46 ± 0.19 0.680b
Docosahexanoic (DHA, C22:6 n-3) 2.35 ± 0.90 2.29 ± 1.03 0.811b
1Enzyme activities (fatty acids
ratios)
   
Elongase 5 (ELOVL5)    
DGLA:GLA 36.26 ± 17.10 34.14 ± 16.23 0.628b
DTA:AAѢ 4.09 ± 0.76 4.49 ± 0.79 0.049b
D5D activity (FADS1)    
AA:DGLA 3.57 ± 0.91 3.58 ± 0.82 0.962b
D6D activity (FADS2)    
DGLA:LAѢ 10.96 ± 3.13 9.35 ± 1.61 0.002b
т Secondary and university. 1 Fatty acids and enzyme activities (control, n= 94;
atopic eczema, n=18). † Mean±SD. ‡ Natural log- transformation. Ѣ Fatty acid
ratios x 100. a Significance for Pearson’s chi-squared test. b Significance for
Student t- test.*p<0.05.
doi: 10.1371/journal.pone.0078245.t001
FADS and ELOVL Gene Expressions and Atopic Eczema
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e78245
level was not significantly different from that of control (-9.40%,
p=0.308) (Figure 2).
Table 3 gives the results of the regression logistic models.
There was no significant association between D5D activity
(AA:DGLA) [OR=1.11, IC-95 (0.60-2.05), p=0.750] and atopic
eczema. D6D activity (DGLA:LA) showed a marginal
association with atopic eczema [OR=0.82, IC-95 (0.66-1.00),
Table 2. Relationship between the mRNA-expression level
of each enzyme and enzyme activity in the peripheral blood
of children.
  Peripheral whole blood mRNA expression
 FADS1 FADS2‡ ELOVL5
FADS1   0.527 **  
ELOVL5 0.160  0.078   
GLA 0.194 * 0.179  - 0.003
DGLA 0.255 ** 0.332 ** 0.031
AA - 0.073  - 0.172  0.027
Enzyme activity      
Δ5-desaturase (FADS1)      
AA:DGLA - 0.342 ** - 0.480 ** - 0.082
Δ6-desaturase (FADS2)      
DGLA:LA 0.218 * 0.328 ** 0.014
Elongase-5 (ELOVL5)      
DGLA:GLA -0.081  0.030  0.014
DTA:AA - 0.038  0.170  0.088
‡ Natural log- transformation. Associations are presented as Pearson’s rank
correlation coefficients. *p<0.05. ** p<0.01.
doi: 10.1371/journal.pone.0078245.t002
Figure 2.  Fatty acid desaturase and elongase mRNA-
expression (mRNA/PPIB mRNA) in peripheral
blood.  Expression levels were normalized using the
expression of PPIB as the endogenous housekeeping gene.
Black bars correspond to the AE children (n=20), and white
bars correspond to the non-AE children (n=104). FADS1
encodes Δ5-desaturase (-9.40%, D5D), FADS2 Δ6-desaturase
(-40.30%, D6D) and ELOVL5 elongase-5 (-20.36%). Each bar
represents the mean ± S.E.M. of the percentage of gene
expression in AE children compared to the reference group,
which showed 100% expression. *p<0.05.
doi: 10.1371/journal.pone.0078245.g002
p=0.057]. On the other hand, elongase-5 activity determined by
DTA:AA ratio showed significant a association with atopic
eczema [OR=2.32, IC-95 (1.09-4.92), p=0.029].
There was a significant association between FADS2
[OR=0.20, IC-95 (0.05-0.74), p=0.017] or ELOV5 [OR=0.97,
IC-95 (0.95-0.99), p=0.016] mRNA-expression and the
prevalence of AE in young children. Furthermore, a positive,
but not significant, trend was found for FADS1 [OR=0.99, IC-95
(0.97-1.00), p=0.089].
Discussion
This is the first study to explore the gene expression of
enzymes involved in LC-PUFA biosynthesis in whole peripheral
blood, its relationship with enzyme activities and association
with AE in 4-year-old children. We studied a subsample of
children who developed AE in their first year of life (16.1% of
total samples analyzed n=124).
First, differences in LC-PUFA levels between AE and non-AE
children were examined. It is known that the skin is the target
organ in patients with atopic eczema; however, previous
studies suggested that the GLA, DGLA and AA present in
epidermal phospholipids are biosynthesized endogenously
elsewhere and transported by the bloodstream to the
epidermis, where phospholipid etherification takes place.
Consequently, serum or plasma phospholipid levels of n-6
PUFAs may reflect their epidermal concentrations [4,28]. Our
results confirmed that children with AE had lower DGLA levels
in their blood than controls. DGLA is a direct precursor of the
series-1 prostaglandins, such as PGE1. This prostaglandin has
potent anti-inflammatory effects and is important for
maintaining healthy skin by regulating water loss and protecting
the skin from injury and infection [29-33]. Accordingly, we found
that GLA was not effectively converted into DGLA in AE
children, therefore indicating a reduction in the amounts and
beneficial effects by action of PGE1. Furthermore, levels of AA,
which is a direct precursor of anti- and pro-inflammatory
mediators, were lower in AE children [3,34-36]. Our results
suggest that an alteration in the endogenous biosynthesis of
DGLA and AA leads to their decreased plasma levels.
Regarding blood n-3 LC-PUFA levels, no changes were
observed in the levels of ALA, EPA and DHA in AE children
compared to controls. The differences in the associations of
n-3 and n-6 LC-PUFAs with AE might be due to the fact that
the former are more dependent on nutritional influences while
the latter rely more on endogenous biosynthesis. These results
are consistent with those reported by other authors in previous
publications [37,38].
It has been hypothesized that the lower levels of n-6 LC-
PUFAs in the serum, plasma or tissues of AE patients are
related to defects in the D6D enzyme (encoded by FADS2)
[3,7,39]. In this study, we observed decreased FADS2
expression in AE children, in accordance with the results of
Saaf et al. [19], who undertook genome-wide expression
profiling in AE. Those authors analyzed the most important
genes in lipid metabolism in the skin of adult AE patients (aged
between 21 and 43 years), and found reduced FADS1 and 2
expressions in AE patients relative to controls. In contrast to
FADS and ELOVL Gene Expressions and Atopic Eczema
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that study, we observed no significant differences in the
expression levels of the FADS1 gene; however, the results had
a similar direction with Saaf (lower FASD1 in AE). Taken
together, these findings suggest that the activity of local
desaturases is predominantly localized in the skin of patients
with severe AE, as seen with the activity of some markers of
chronic inflammation and Th1 response, which are presented
predominantly in the skin but not in the blood of AE patients
[40]. Regarding elongase-5 expression, AE children had lower
ELOVL5 mRNA levels in their blood than their healthy
counterparts. Therefore, these results could explain why AE
children have lower levels of DGLA and AA, since D6D and
elongase-5 directly participate in the biosynthesis of these fatty
acids.
Assessing the relationship between gene expression and
fatty acid levels, we found that DGLA levels and D6D activity
(DGLA:LA ratio) were directly associated with FADS1 and
FADS2 gene expression. However, we did not find any
relationship between activity (estimated by DTA:AA ratio) and
mRNA-expression of elongase-5. This might be explained by
the participation of other enzymes in the elongation of AA into
DTA. Indeed, recent studies in several transgenic mouse
models and cell cultures suggest that elongase-2 (encoded by
ELOVL2) also participate in the elongation of AA [41].
Accordingly, in our study, AE and non-AE children displayed
similar plasma levels of DTA, but different AA levels. We also
measured elongase-5 activity using the DGLA:GLA ratio;
however, there was no link between mRNA-expression and
enzyme activity. In summary, the fatty acid ratios can be used
to estimate D5D and D6D activities, but not that of elongase-5
in peripheral blood.
Our results suggested that decreased FADS2 and ELOVL5
mRNA-expression in the blood could contribute to the
development of AE in the first 4 years of life. Lower DGLA:LA
ratios were associated with AE in an unadjusted multiple
logistic regression model. When the regression was adjusted
for the confounders (maternal education, predominant
breastfeeding and sex), this relationship became non-
significant as these confounders also modulated plasma fatty
acids levels, as already demonstrated in previous studies
[14,22]. Collectively, these data support the conclusion that the
n-6 LC-PUFA deficits observed in 4-year-old AE children could
be due to the reduced expression of the genes encoding Δ6-
desaturase and elongase-5.
The main limitation of this study was the sample size
because we analyzed only a subsample of the Sabadell cohort
(in total, 657 neonates were recruited at birth between 2004
and 2006). However, for this study we selected only severe
cases of AE. Thus, we consider the size of the subsample
enough, since the cases of children affected with this skin
disorder represented the 16.1 % of the total cases studied.
Moreover, complementary studies regarding the impact of
different genetic variants (FADS and ELOVL SNPs genotypes)
on gene expression would be of great interest. Therefore, the
results from our study need to be interpreted with caution and
further replications in other cohorts are required to support our
conclusions.
Conclusion
This is the first study to confirm that FADS2 and ELOVL5
mRNA-expression is significantly lower in the peripheral blood
of young children with atopic eczema. These changes in gene
expression may explain the low concentration of n-6 LC-PUFAs
in children who develop this skin disorder in their early
childhood.
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Table 3. Association between enzyme activities, mRNA expression of each enzyme and atopic eczema.
 N (AE/control) OR unadjusted 95%-CI p-value N (AE/control) OR adjusted1 95%-CI p-value
Enzyme activities         
D5D (AA/DGLA) 18/94 1.01 0.58 - 1.79 0.962 16/92 1.11 0.60 - 2.05 0.750
D6D(DGLA/LA) 18/94 0.82 0.67 - 0.99 0.041 16/92 0.82 0.66 - 1.00 0.057
ELOVL5 (DGLA/GLA) 18/93 0.63 0.20 - 2.04 0.444 16/91 0.98 0.26 - 3.64 0.970
ELOVL5 (DTA/AA) 18/94 1.90 0.99 - 3.64 0.054 16/92 2.32 1.09 - 4.92 0.029
mRNA expression         
FADS1 (D5D) 20/104 0.99 0.98 - 1.01 0.306 18/99 0.99 0.97 - 1.00 0.089
FADS2 (D6D) 19/103 0.42 0.17 - 1.04 0.061 17/98 0.20 0.05 - 0.74 0.017
ELOVL5 (Elongase-5) 20/104 0.97 0.97 - 0.99 0.006 18/99 0.97 0.95 - 0.99 0.016
Odd ratios (OR) of measured mRNA expression and enzyme activities on eczema atopic are estimated by logistic regression. 1Adjusted for maternal education, sex and
predominant breastfeeding (> 2 weeks).
doi: 10.1371/journal.pone.0078245.t003
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